Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy

Detalhes bibliográficos
Autor(a) principal: Dias,Bruno L. Scofano
Data de Publicação: 2017
Outros Autores: Fernandes,Alexandre R., Maia Filho,Heber de S
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000500282
Resumo: ABSTRACT Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production. There are no published studies about its use in children with cerebral palsy. Objective To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial. Results Twenty-five children were assessed. The difference in the mean scores of the pre- and post-treatment scales reached statistical significance. There was a low frequency of side effects compared to studies with other anticholinergics. Conclusion The use of sublingual atropine sulfate seems to be safe and there is a reduction in the Drooling Impact Scale score, which suggests efficacy in the treatment of drooling in children and adolescents with cerebral palsy. Our results should be replicated in randomized, placebo-controlled studies with larger numbers of participants.
id ABNEURO-1_0a9c88c2b18fb908ea032363df815e76
oai_identifier_str oai:scielo:S0004-282X2017000500282
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsycerebral palsysialorrheachilddrug therapyatropineABSTRACT Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production. There are no published studies about its use in children with cerebral palsy. Objective To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial. Results Twenty-five children were assessed. The difference in the mean scores of the pre- and post-treatment scales reached statistical significance. There was a low frequency of side effects compared to studies with other anticholinergics. Conclusion The use of sublingual atropine sulfate seems to be safe and there is a reduction in the Drooling Impact Scale score, which suggests efficacy in the treatment of drooling in children and adolescents with cerebral palsy. Our results should be replicated in randomized, placebo-controlled studies with larger numbers of participants.Academia Brasileira de Neurologia - ABNEURO2017-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000500282Arquivos de Neuro-Psiquiatria v.75 n.5 2017reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20170033info:eu-repo/semantics/openAccessDias,Bruno L. ScofanoFernandes,Alexandre R.Maia Filho,Heber de Seng2017-05-30T00:00:00Zoai:scielo:S0004-282X2017000500282Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2017-05-30T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
title Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
spellingShingle Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
Dias,Bruno L. Scofano
cerebral palsy
sialorrhea
child
drug therapy
atropine
title_short Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
title_full Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
title_fullStr Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
title_full_unstemmed Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
title_sort Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy
author Dias,Bruno L. Scofano
author_facet Dias,Bruno L. Scofano
Fernandes,Alexandre R.
Maia Filho,Heber de S
author_role author
author2 Fernandes,Alexandre R.
Maia Filho,Heber de S
author2_role author
author
dc.contributor.author.fl_str_mv Dias,Bruno L. Scofano
Fernandes,Alexandre R.
Maia Filho,Heber de S
dc.subject.por.fl_str_mv cerebral palsy
sialorrhea
child
drug therapy
atropine
topic cerebral palsy
sialorrhea
child
drug therapy
atropine
description ABSTRACT Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production. There are no published studies about its use in children with cerebral palsy. Objective To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial. Results Twenty-five children were assessed. The difference in the mean scores of the pre- and post-treatment scales reached statistical significance. There was a low frequency of side effects compared to studies with other anticholinergics. Conclusion The use of sublingual atropine sulfate seems to be safe and there is a reduction in the Drooling Impact Scale score, which suggests efficacy in the treatment of drooling in children and adolescents with cerebral palsy. Our results should be replicated in randomized, placebo-controlled studies with larger numbers of participants.
publishDate 2017
dc.date.none.fl_str_mv 2017-05-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000500282
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2017000500282
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x20170033
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.75 n.5 2017
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212782437302272

Registros relacionados